Aurora Private Wealth Inc. Makes New $4.48 Million Investment in Amgen Inc. (NASDAQ:AMGN)

Aurora Private Wealth Inc. bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 14,388 shares of the medical research company’s stock, valued at approximately $4,483,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital World Investors lifted its position in shares of Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the last quarter. Norges Bank acquired a new position in Amgen during the fourth quarter worth about $1,541,991,000. GAMMA Investing LLC lifted its holdings in shares of Amgen by 43,573.5% in the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after acquiring an additional 3,653,205 shares during the last quarter. Capital International Investors boosted its stake in shares of Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after purchasing an additional 3,495,503 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the sale, the senior vice president now owns 8,162 shares in the company, valued at $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Amgen Trading Up 1.9%

Amgen stock opened at $277.49 on Wednesday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market capitalization of $149.21 billion, a price-to-earnings ratio of 25.32, a P/E/G ratio of 2.46 and a beta of 0.51. The firm has a 50 day moving average of $281.03 and a 200 day moving average of $286.04. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the firm earned $3.96 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AMGN shares. Guggenheim started coverage on shares of Amgen in a research report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 target price on the stock. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday. Royal Bank Of Canada lowered their target price on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. UBS Group restated a “neutral” rating and set a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $305.00 price objective on shares of Amgen in a report on Tuesday. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.